Skip to main content

Search

Reset all filters
398 Result(s)
Sort by

Agreement-to-acquire-NBE-Therapeutics

Agreement-to-acquire-NBE-Therapeutics

Boehringer Ingelheim to acquire NBE-Therapeutics to significantly enhance cancer pipeline portfolio with antibody-drug conjugates.
Partnering in Retinal Health

Partnering in Retinal Health

Our partnering interests in retinal diseases offer opportunities for collaboration to complement our pipeline and advance treatment and delivery.
Open Innovation at Boehringer Ingelheim

Open Innovation at Boehringer Ingelheim

Learn more about how we’re working across the innovation community to advance research and accelerate the development of new medicines
Bluetongue disease

Bluetongue disease

The bluetongue virus is a viral disease that affects ruminants' health. It doesn't affect humans, but it is a threat to animals.
Retinal Health Research

Retinal Health Research

Our research is targeting key mechanisms in the pathogenesis of retinal diseases – vascular dysfunction, neuronal dysfunction and neuronal inflammation.
Our Partners_ViraTherapeutics

Our Partners_ViraTherapeutics

Lisa Egerer, COO and Patrik Erlman, Head of Research at ViraTherapeutics talk about their partnering journey with Boehringer Ingelheim.
Vetmedin®

Vetmedin®

Treatment of canine congestive heart failure originating from dilated cardiomyopathy or valvular insufficiency (mitral and/or tricuspid regurgitation).
Thelaziosis dog eyeworms

Thelaziosis dog eyeworms

Have you heard of Thelaziosis? In Europe, some fruit flies host an emerging parasite known as “eyeworm”, an infestation which causes more or less severe conjunctivitis, sometimes leading to corneal ulcers and even blindness in dogs.
Taking cancer on together

Taking cancer on together

Through their work, our colleagues from around the world hope to empower patients to Take Cancer On.